Occurrence and protective level of influenza infections using serology in patients with COPD in vaccination study

Journal of the Medical Association of Thailand

Volumn 87, Issue 8, 2004, Pages 964-969

  Kositanont, Uraiwan ^a   Kanyok, Raweewan ^a   Wasi, Chantapong ^a   Wongsurakiat, Phunsup ^a   Suthamsmai, Tasneeya ^a   Maranetra, Nanta ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Diagnosis; Incidence; Influenza; Occurrence; Prevalence; Protective antibody; Vaccine

Indexed keywords

INFLUENZA VACCINE; PLACEBO; TRIPLE VACCINE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEMAGGLUTINATION INHIBITION TEST; HIGH RISK PATIENT; HUMAN; IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INFLUENZA VIRUS B HARBIN 07 94; MAJOR CLINICAL STUDY; SEROEPIDEMIOLOGY; SEROLOGY; VIRUS STRAIN;

AGED; ANTIBODIES, VIRAL; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEROEPIDEMIOLOGIC STUDIES;

EID: 4544355384     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Carilli AD, Cohd RS, Gordon W. A virologic study of chronic bronchitis. N Eng J Med 1964; 270: 123-7.
2. Rothbart PH, Kempen BM, Sprenger MJW. Sense and nonsense of influenza vaccination in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Med 1995; 151: 1682-6.
3. The COPD guidelines groups of the standards of care committee of the BTS: BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52(suppl 5): S1-28.
4. Lamb RA, Krug RM. Genes and proteins of the influenza viruses. In: Fraenkel-Conrat H, Wagner RR, eds. The influenza viruses. New York: Plenum Press, 1989: 1-88.
5. rd ed. Lippincott-Raven Publishers, Philadelphia, Pa. 1996: 1397-445.
6. th edn. Washington: American Public Health Association, Inc, 1989: 631-68.
7. Thawatasupha P, Maneewong P, Prasittikhet K, et al. Local strain influenza viruses isolated during the period 1998-1999. J Health Science 2000; 9: 551-7.
8. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis 1976; 113: 465-70.
9. Howells CHL, Tyler LE. Prophylactic use of influenza vaccine in patients with chronic bronchitis. Lancet 1961; 30: 1428-32.
10. Eadie MB, Stott EJ, Grist NR. Virological studies in chronic bronchitis. BMJ 1966; 2: 671-3.
11. Fox R, French N, Davis L, et al. Influenza immunization status and viral respiratory tract infections in patients with chronic airflow limitation. Respir Med 1995; 89: 559-61.
12. Monto AS, Ohmit SE, Margulies JR, Talsma A. Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity. Am J Epidemiol 1995; 141: 502-6.
13. Fell PJ, O'Donnell HF, Watson NP, et al. Longer term effects of influenza vaccine in patients with chronic pulmonary disease. Lancet 1977; 18: 1282-4.
14. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals; a randomized doulbe-blind placebo-controlled trial. JAMA 1994; 272: 1661-5.
15. Kilboure ED. Inactivated influenza vaccine. In: Vaccine second edition, Re 59, 1994: 565-81.
16. Gorss PA, Quinnan GB, Rodstrein N, LaMontagne TR, et al. Association of influenza immunization with reduction in mortality in an elderly population. A prospective study. Arch Intern Med 1988; 148: 562-5.
17. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses, J Hyg (Lond) 1972; 70: 767-77.
18. Potter CW, Jennings R, Nicholson K, Tyrrell DA, Dickinson KG. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J Hyg (Lond) 1977; 79: 321-32.
19. Codon Meiklejohn. Viral Repiratory disease at lowry air force base in denver 1952-1982. J Infect Dis 1983; 148: 775-84.
20. Hobson D, Curry RL, Beare AS. Hemagglutination-inhibiting antibody titers as a measure of protection against influenza in man. Immunobiol Stand 1973; 20: 164.
21. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35: 69-75.
22. Davenport FM. Inactivated influenza virus vaccines. Past, present, and future. Am Rev Respir Dis 1961; 832: 146-56.
23. Farnik J, Bruj J. An outbreak of influenza A2 in a population with a known antibody profile. J Infect Dis 1966; 116: 425-8.
24. Couch RB, Douglas RG Jr, Fedson DS, Kasel JA. Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J Infect Dis 1971; 124: 473-80.
25. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974; 129: 411-20.
26. Murphy BR, Chalhub EG, Nusinoff SR, Kasel J, Chanock RM. Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. J Infect Dis 1973; 128: 479-87.
27. Foy HM, Cooney MK, McMahan R. A Hong Kong influenza immunity three years after immunization. JAMA 1973; 226: 758-61.
28. Couch RB, Kasel JA, Glezen WP, et al. Influenza: its control in persons and populations J Infect Dis 1986; 153: 432-40.
29. Wijma G, Lighart GJ. Influenza vacination for all elderly. Gerontology. 1996; 42: 270-3.